▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1624 by analyst upside · 2026-11-13
BVS
Bioventus Inc.
Healthcare · Market Cap $744M · P/E 13.4x
ANALYST PRICE TARGET
+52.9%
implied upside to consensus target
Current Price $10.86
Consensus Target $16.6
Bull Target $18.0
Bear Target $15.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
0
Sell
0
52-Week Low $6.47
52-Week High $15.89
YTD Return +50.6%
FUNDAMENTALS
Market Cap $744M
P/E Ratio (TTM) 13.4x
Forward P/E 12.2x
EPS (TTM) $0.81
PEG Ratio 1.24
Dividend Yield N/A
Revenue (TTM) $586M
Profit Margin 9.8%
52-WEEK RANGE
52-Week Low $6.47
52-Week High $15.89
Current Price $10.86
Bear Target $15.0
Bull Target $18.0
● Now $10.86 ● Target $16.6
TRADING DATA
Avg Volume 541K
YTD Return +50.6%
Analyst Count 5
Consensus Buy
Upside to Target +52.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Bioventus Inc. (BVS) is currently trading at $10.86 with a Wall Street consensus price target of $16.6, implying potential upside of 52.9% over the next 12 months. 5 analysts currently cover BVS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $15.0.

BVS operates in the Healthcare sector with a market capitalisation of $744M. The stock is up 50.6% year-to-date and is currently trading near the lower end of its 52-week range of $6.47 – $15.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-11-03 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-17 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-08-17 40% win rate (10 calls)
Barrington Research - Reiterated
Outperform → Outperform 2026-06-30 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-16 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-05-22 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-03-06 Building track record
Craig-Hallum - Reiterated
Buy → Buy 2026-03-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
14/30
Consensus clarity
24/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →